What is the recommended duration for tapering dexlansoprazole (Dexilant) 30 mg, and can I taper after one month and switch to famotidine (Pepcid)?

Dexlansoprazole 30mg Tapering Strategy

For most patients on dexlansoprazole 30mg, a one-month course followed by a direct switch to famotidine is appropriate, but the decision depends on your original indication and symptom severity. 1

Understanding Your Current Therapy

Dexlansoprazole 30mg is a maintenance dose typically used after healing erosive esophagitis or for long-term GERD symptom control. 1, 2 The 30mg dose maintains healing in approximately 66-75% of patients with previously healed erosive esophagitis over 6 months. 2

When One Month Is Sufficient

You can taper after one month and switch to famotidine if:

• You were started on dexlansoprazole for non-erosive GERD or mild symptoms without endoscopic confirmation of erosive disease 1
• Your symptoms have completely resolved and you've been heartburn-free for at least 2-4 weeks 1
• You never had documented Los Angeles Grade C or D erosive esophagitis 1
• You're taking dexlansoprazole without a clear ongoing indication (up to 70% of chronic PPI prescriptions are potentially inappropriate) 1

When Longer Duration Is Needed

Continue dexlansoprazole 30mg for a full 6 months before considering a taper if:

• You had documented erosive esophagitis (any Los Angeles grade) that required healing 2
• You're on dual antiplatelet therapy or have high GI bleeding risk requiring gastroprotection 1
• You experienced symptom relapse when attempting previous PPI discontinuation 1

The Famotidine Switch Protocol

Direct substitution without a gradual PPI taper is the recommended approach:

1. Stop dexlansoprazole 30mg abruptly (no gradual dose reduction needed for this medication class) 1

2. Start famotidine 20mg twice daily (before breakfast and before dinner) on the same day you stop the PPI 1

3. Expect rebound acid hypersecretion for approximately 2-3 weeks after stopping the PPI—this is a physiologic withdrawal phenomenon caused by hypergastrinemia-induced parietal cell proliferation during chronic PPI use, not a return of your original disease 1

4. Famotidine will partially blunt but not completely prevent rebound symptoms during this 2-3 week window 1

Why Famotidine Is the Appropriate Step-Down Agent

• Famotidine (an H2-receptor antagonist) provides acid suppression without the CYP2C19 interactions or cognitive concerns associated with PPIs 1
• It shows no evidence of impairing cognitive function, making it safer for long-term use if ongoing acid suppression is needed 1
• Famotidine is specifically recommended as an alternative for patients with memory concerns or those on clopidogrel 1

Managing Rebound Symptoms

During the 2-3 week rebound period:

• Use antacids (calcium carbonate or magnesium hydroxide) as needed for breakthrough symptoms 1
• Maintain famotidine 20mg twice daily consistently—do not increase the dose 1
• Avoid restarting the PPI unless symptoms become severe and unmanageable 1
• Symptoms should progressively improve after week 2-3 as parietal cell mass returns to baseline 1

Red Flags Requiring Endoscopy Before Tapering

Do not attempt tapering without upper endoscopy if you have:

• Persistent symptoms despite 8 weeks of twice-daily PPI therapy 1
• Alarm symptoms: dysphagia, odynophagia, unintentional weight loss, or GI bleeding 1
• Never had endoscopy to confirm your diagnosis 1

Alternative: The Conservative Approach

If you're uncertain about your original indication or concerned about symptom relapse:

1. Continue dexlansoprazole 30mg for 3-6 months total 2
2. Then attempt a trial off all acid suppression for 2-4 weeks to assess if you truly need ongoing therapy 1
3. If symptoms recur, restart famotidine 20mg twice daily rather than returning to the PPI 1
4. Reserve PPI restart only for documented erosive disease or severe refractory symptoms 1

Common Pitfalls to Avoid

• Do not gradually reduce dexlansoprazole from 30mg to 15mg—there is no 15mg dose, and "tapering" a PPI by dose reduction does not prevent rebound acid hypersecretion 1
• Do not switch to omeprazole or esomeprazole if you're on clopidogrel—these agents significantly inhibit CYP2C19 and reduce antiplatelet efficacy; pantoprazole would be the safer PPI alternative if you must stay on a PPI 1
• Do not assume symptom recurrence in weeks 1-2 off the PPI represents treatment failure—this is likely rebound hypersecretion, which resolves spontaneously by week 3 1
• Do not continue PPI therapy indefinitely without reassessing the indication within 12 months—regular review of ongoing need is essential 1

Bottom Line

For uncomplicated GERD without documented erosive disease, one month of dexlansoprazole 30mg followed by a direct switch to famotidine 20mg twice daily is reasonable and aligns with guideline recommendations to minimize unnecessary PPI exposure. 1 If you had confirmed erosive esophagitis, complete the full 6-month maintenance course before attempting the switch. 2